Covid-19: Razvoj vakcine, imunitet i primena medikamenata

[vememah]

Quote

As with the Moderna and BioNTech/Pfizer vaccines, CureVac’s jab uses mRNA but its mRNA is natural and unmodified. Its shot also uses a lower dose, 12 micrograms compared to Moderna’s 100mcg and BioNTech/Pfizer’s 30mcg, which results in a lower cost of production, and is stable at conventional fridge temperatures.

https://www.ft.com/content/0309b8ae-bae8-42ce-99e9-d487cd43899c

Edited June 17, 2021 by vememah

[vememah]

Quote

U FOKUSU

Kako je Kjurvek prokockao šansu veka

 

Dugo se mislilo da će prvi razviti vakcinu protiv korone, ali onda su ih drugi prestigli. Sada je pitanje da li će cepivo nemačkog Kjurveka uopšte dobiti dozvolu. Prve studije su poražavajuće.

Velika prašina digla se prošlog proleća kad se čulo da je Donald Tramp navodno ponudio milijardu evra da Kjurvek (Curevac), firma iz nemačkog Tibingena, pravi vakcine protiv korone samo za američko tržište. Ta nepristojna ponuda je odbijena, a Kjurvek je ostao najveća evropska nada, posebno kada se uortačio sa gigantom farmaceutske industrije Bajerom koji je trebalo da masovno proizvodi cepivo.

Nada je bila uzaludna, kako se ispostavilo. Ne samo da su nekoliki proizvođači napravili cepivo pre ove firme, već sada podaci kažu da Kjurvekova vakcina – koja je još u fazi ispitivanja – ima efikasnost od svega 47 odsto, nedovoljnu da dobije dozvolu. Kako je saopšteno, prvi presek pokazuje da delotvornost cepiva zavisi od starosti ljudi, kao i varijante korona-virusa.

U pitanju su tek međurezultati, ali vrednost akcija firme iz Tibingena na Vol stritu smesta je opala za polovinu.

Veliko razočaranje

Kjurvekovo cepivo, bazirano na mRNA tehnologiji kao i Bajontekovo i Modernino, nalazi se u poslednjoj fazi kliničkih ispitivanja sa 40.000 dobrovoljaca. U toj fazi, jedan deo njih dobija vakcinu, a drugi placebo, a onda se prati iz koje od te dve grupe se koliko ljudi zarazi koronom u svakodnevnom životu i kakav im je tok bolesti.

Prema saopštenju Kjurveka, do sada je otkriveno trinaest različitih varijanti korona-virusa među njihovim dobrovoljcima. Samo jedan jedini slučaj otpada na izvornu varijantu koja se proširila iz Kine, što govori da su mutacije potpuno preuzele primat.

Sada je izvesno da Kjurvekovo cepivo neće već u junu dobiti dozvolu Evropske agencije za lekove, a pitanje je da li će je dobiti uopšte. „Konačna efikasnost bi još mogla da bude drukčija“, rekao je generalni direktor firme Franc-Verner Has, priznajući da je očekivao bolje međurezultate.

Bolje rezultate je očekivao i nemački ministar zdravlja Jens Špan koji sada govori o „velikom razočaranju“.

EU htela 405 miliona doza

Nije ni čudo – Nemačka je već do kraja juna bila računala sa 1,4 miliona doza od Kjurveka. Evropska unija je unapred obezbedila ukupno 405 miliona doza ove vakcine koja, kako se čini, nikada neće ni krenuti u masovnu proizvodnju.

Menadžer magazin, koji se bavi temama iz poslovnog sveta, piše da je Kjurvek „prokockao šansu veka“. Prema viđenju tog magazina, milijarder i investitor Ditmar Hop poverio je stvar pogrešnom menadžmentu.

Drukčije se stvar odvijala u Majncu, gde je sedište Bajonteka koji je, u saradnji sa američkim Fajzerom, razvio prvu na zapadu odobrenu vakcinu protiv korone. Bajontekova vrednost je skočila u nebesa, a vodeći naučnik i osnivač firme Ugur Šahin došao je do bogatstva koje se procenjuje na 8,6 milijardi dolara.

https://www.dw.com/sr/kako-je-kjurvek-prokockao-šansu-veka/a-57932116

Edited June 17, 2021 by vememah

[vememah]

 

[precog]

astro zecevi, objavljena studija oksford univerziteta prema kojoj ta vakcina stiti od novih delta i kappa sojeva. testirali su antitela vakcinisanih ljudi i sposobnost da neutralisu virus.

[Friend]

On 21.6.2021. at 21:38, vememah said:

 

 

Poprilicno razocarenje jer mi je kjurvak bio nekako prvi pik uz mozda novavax. Samo glasno razmisljam, jer do Srbije ovo ne bi ni stiglo.

 

Steta, da li je je samo zbog male doze ili zbog netaknutog mrna jos ne znaju.

[vememah]

Quote

 

Why we don't believe any Covid variant will be able to defeat our jab completely: Creators of the Oxford vaccine SARAH GILBERT and CATH GREEN give a very reassuring answer to the question that haunts us all
...
New variants are inevitable and we had expected them, but we had not, perhaps, anticipated that they would emerge quite as fast as they did. 

At our Clinical Biomanufacturing Facility, in Oxford, we had even allowed ourselves to relax a little, thinking our job with Covid-19 was done and we could start to 'go back to normal'.

By early 2021 we knew of three variants of concern – Kent, South African and Brazilian. And by early February, we had good evidence that the vaccine still worked against the Kent variant, so we focused on the other two.

The signs were good that our vaccine would still prevent death and severe disease, but it looked like they were unlikely to do as well in preventing mild and asymptomatic cases. Later on, of course, we had to think about the Delta variant, which was even more transmissible than the Kent variant.

Happily, we didn't have to make new vaccines from scratch. Instead we would use the methods we'd used in 2020 – we just needed the genetic code for the mutated virus.

We also wouldn't need to repeat all the clinical trials, since this was just a tweak of the original vaccine, and if the vaccine behaved as expected we should have a booster shot by the autumn of 2021.

One day we might be able to design one vaccine that works well against multiple variants (not forgetting that the existing vaccines do, to some extent, still work against them all). We even might be able to design pre-emptive vaccines against variants that we have not yet seen. None of these issues feel insurmountable.

The good news is that we also think it is unlikely that the virus can mutate in a way that keeps it functioning but makes our vaccine completely ineffective.

That's because a change in the spike protein – which allows the coronavirus to enter and infect human cells – that is radical enough to make our vaccine completely ineffective would also, almost certainly, be so extreme as to make the virus non-functional. So although it feels like Groundhog Day, and although we are all exhausted and wondering when it will ever end, we are tackling the new variant situation with our teeth gritted and the fortifying knowledge that we know more about what we are doing and where we are headed.

We don't know how many more versions of the vaccine we might be asked to make over the next year, but as global vaccination programmes get going, less coronavirus will be in circulation, making the chances of new variants decline, too.
...

 

https://www.dailymail.co.uk/news/article-9728519/Why-dont-believe-Covid-variant-able-defeat-jab-completely.html

[Time Crisis]

Quote

(CNN)Germany has issued what appears to be the strongest recommendation anywhere for the mixing of Covid-19 vaccines on efficacy grounds.

 

The German Standing Committee on Vaccination (STIKO) said Thursday that people who receive a first dose of the Oxford-AstraZeneca vaccine "should get an mRNA vaccine as their second dose, regardless of their age."

This makes Germany one of the first countries to strongly recommend that people who have received a first dose of AstraZeneca receive either a Pfizer-BioNTech or Moderna vaccine as their second dose.

German Chancellor Angela Merkel helped pave the way for mixed vaccine use when she received the Moderna shot in June as her second dose following a first dose of the AstraZeneca vaccine.

STIKO said that "current study results" show that the immune response generated after a mixed dose vaccination "is clearly superior."

The mRNA vaccines currently approved by the European Medicines Agency (EMA) are Pfizer-BioNTech and Moderna.

 

Canada's National Advisory Committee on Immunization made a weaker recommendation on June 17 when they said that "an mRNA vaccine is now preferred as the second dose for individuals who have received a first dose of AstraZeneca/COVISHIELD vaccine."

 

[vememah]

 

[Have_Fun]

Ministarstvo zdravlja Izraela saopštilo je da efikasnost Fajzerove vakcine manja zbog delta varijante koronavirusa i da sprečava samo 64 procenta infekcija, dok je zaštita od teških oblika kovida 19 ostala visoka. Prema novim podacima ministarstva, efikasnost vakcine Fajzer/Biontek značajno se smanjila u poslednjih nekoliko nedelja kako se agresivnija Delta varijanta koronavirusa proširila, pa je od 6. juna efikasnost vakcinacije u sprečavanju infekcije pala na 64 procenta u odnosu na 95,3 koliko je iznosila kad je dominantan bio Alfa soj, prenosi CNN.


E pa... jebiga bas...

[vememah]

 

[Aleksija]

F.D.A. Will Attach Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine Federal regulators concluded that the risk of developing the syndrome was low, and that the benefits of the vaccine still strongly outweigh it.

[Lezilebovich]

12 hours ago, Aleksija said:

F.D.A. Will Attach Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine Federal regulators concluded that the risk of developing the syndrome was low, and that the benefits of the vaccine still strongly outweigh it.

 

sa jedne strane, stvarno je fer što se objavljuju ovakve informacije, ali već vidim kako se sipa ovo gorivo u antivaxx buldožer. a 

[precog]

mora sve da se objavi, jedino tako se stice poverenje. a sad je na ekspertima da stave u kontekst i komuniciraju siroj publici.

edit. a i obavezni su da objavljuju

Edited July 13, 2021 by precog

[Friend]

Antivaxeri idu na prokuzavanje tako da nema veze. Ovo su informacije za one koji se vakcinisu.

[aram]

Izvinte, malo sam se pogubio, J&J je i dalje jedna doza ili su dve?